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Abstract. Orphan drugs (ODs) are medicinal products intended for diagnosis, prevention
ortreatmentoflife-threateningorveryseriousdiseasesaffectinglessthan5in10000people
in the European Union (EU). These drugs are called “orphans” because the pharmaceutical
industry has little interest, under normal market conditions, in developing and marketing
products intended for only a small number of patients suffering from very rare conditions.
Because of the small market, ODs are often very expensive. Whereas decisions surrounding
orphan designation and marketing authorization of ODs are taken at the EU level, decisions
governing pricing and reimbursement of ODs are a member state responsibility. In Latvia
drug reimbursement covers drugs which are included in the national reimbursement drug
list or, based on the medical council’s decision, drugs can also be reimbursed within the
framework of individual reimbursement system with limit of 10000 LVL (C14 229) per
patient per year. Due to the big costs and the small number of patients ODs are often not
included in the reimbursement list and therefore are reimbursed individually.
Introduction
Rare diseases, also related to as orphan diseases, are life-threatening or chronically debilitating
conditions of different origin. The majority of them are genetic disorders, others being rare cancers,
congenital malformations, autoimmune, toxic and infectious diseases. Disease is considered as rare if it
affects not more than 5 in 10000 people in the EU. It is estimated that between 5000 and 8000 different
rare conditions exist, affecting 6–8% of the population, concluding that about 30 million people are
suffering from rare diseases in the EU (Communication from the European Commission, 2008). The
EU offers a range of incentives to foster the development of ODs including assistance with medicine
development, reduced fees for marketing authorization, protection from market competition once the
medicine is authorized (10 years of marketing exclusivity) (Regulation No. 141/2000, 2000). Orphan
designation refers to awarding of orphan status to a medicine, but marketing authorization refers to
the approval to market the medicine. While many drugs may have received an orphan designation, few
have received a marketing authorization. In April 2013 there were 918 positive opinions on orphan
designation and 65 ODs authorized in the EU. Four drugs were withdrawn from use in the EU, 11 ODs
were removed from the EU register of orphan medicinal products, and six drugs have already completed
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their period of market exclusivity (EMA list of rare disease designations, 2013; Community register of
designated orphan medicinal products, 2013).
Whereas decisions surrounding orphan designation and marketing authorization of ODs are
taken at the EU level, decisions governing pricing and reimbursement of ODs are a member
state responsibility. Furthermore accessibility of a certain OD in a certain country depends on
the strategy of the pharmaceutical company and the decision taken by national health authorities
concerningreimbursement.DrugreimbursementcoversdrugswhichareincludedintheLatviannational
reimbursement drug list, or based on the medical council’s decision, drugs can also be reimbursed within
the framework of individual reimbursement system with limit of 10 000 LVL (C14 229) per patient
per year (Ministru kabineta noteikumi Nr. 899, 2006). Currently 29 ODs are available on Latvian
market, including 4 drugs that were originally designated ODs, but further withdrawn from the EU
register of designated orphan medicinal products upon request of the sponsor (eltrombopag, everolimus,
imatinib, and sunitinib) (Latvijas Republikas Z¯ al ¸u re‘ gistrs, 2013). Three drugs are included in the
reimbursement list C (imatinib, dasatinib, and nilotinib) all indicated for Philadelphia chromosome
positive chronic myeloid leukemia (Kompens¯ ejamo z¯ al ¸u saraksts, 2013). 13 drugs were reimbursed
within the framework of individual reimbursement system in 2008–2012, and four drugs (betaine,
idursulfase, mecasermin, and sapropterin) were provided within the programme of medicinal treatment
of rare diseases in children. ODs are distributed by both hospital and community pharmacies in Latvia.
This study aims to determine the trends in reimbursement of ODs in Latvia within the framework of
individual reimbursement system in 2008–2011.
Materials and methods
Current study includes two types of medicinal products intended for rare diseases in Europe: ODs
with European orphan designation and European marketing authorization, and drugs with European
marketing authorization without orphan designation in Europe (European orphan designation has not
been granted or the designation was removed/withdrawn). These medicinal products may have been
granted, or not, an orphan designation in another geographical area in the world. European register
of designated orphan medicinal products (http://ec.europa.eu/health) was used to identify ODs with
European orphan designation and European marketing authorization. While drugs intended for rare
diseases with European marketing authorization without orphan designation in Europe were identiﬁed
by using Orphanet database (http://www.orpha.net).
Availability of the above mentioned drugs in Latvia was determined by using National Register
of Human Medicines maintained by State Agency of Medicines of Latvia (http://www.zva.gov.lv). Data
fromtheNationalHealthService(http://www.vmnvd.gov.lv)annualreportsonthestatebudgetspending
on drug reimbursement within four years (2008–2011) were used to analyze individual reimbursement
of distinct ODs.
Results
An average of C831 475 annually were spent on individual reimbursement in Latvia within 4 years, of
which an average of 67.7% were spent on OD reimbursement. Number of patients receiving these drugs
increased from 46 patients in 2008 to 129 patients in 2011 (by 180.4%). Besides, the annual cost per
patient decreased by 52.8%, resulting in an average of C7 904 per patient per year. Mean 21 different
ODs were reimbursed annually, almost a half of which (mean 49.5%) are drugs for the treatment of
oncologic diseases, for 24 different diagnoses (Table 1).
Most patients were receiving drugs for treatment of various types of tumors (mean 50.1%) followed
by cardiopulmonary diseases (mean 27.2%) (Fig. 1). Therefore, most costs were spent on anti-neoplastic
drugs (mean 61.1%) and drugs for cardiopulmonary diseases (mean 27.1%) (Fig. 2). Moreover there
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Table 1. Characteristics of OD individual reimbursement (by year).
Characteristics
Year
2008 2009 2010 2011
Number of patients received ODs 46 66 70 129
Individual reimbursement (C) 675 805 804 364 717 337 1 128 393
Individual reimbursement of ODs (C) 492 731 611 529 460 988 651 832
Annual cost of ODs (C per patient) 10 712 9 266 6 586 5 053
Number of ODs reimbursed 20 21 19 23
Number of diagnoses covered by ODs 21 25 24 26
Figure 1. Proportion of patients by therapeutic area.
was a tendency observed that share of antineoplastic drugs was decreasing, while share of drugs for
cardiopulmonary diseases was increasing in both terms (number of patients, and resources spent).
Antineoplastic drugs had the highest annual cost per patient (mean C9 682) though they decreased
most notably (by 53.8%), while drugs for diseases of the nervous system (mean C1 785) and endocrine
and metabolic diseases (mean C5 135) had the lowest annual cost per patient.
Oncologic drugs included in the analysis are indicated for such rare conditions as advanced renal
cell carcinoma (sorafenib, temsirolimus, sunitinib, and pazopanib), chronic lymphocytic leukemia
(ofatumumab, rituximab, and alemtuzumab), Philadelphia chromosome positive chronic myeloid
leukemia (imatinib and dasatinib). Rare cardiopulmonary diseases are represented mostly by pulmonary
arterial hypertension (sildenaﬁl and ambrisentan). While diseases of the nervous system include
refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy
(stiripentol), amyotrophic lateral sclerosis (riluzole), partial onset seizures in patients with epilepsy,
myoclonic seizures in patients with juvenile myoclonic epilepsy, and primary generalized tonic-clonic
seizures in patients with idiopathic generalized epilepsy (levetiracetam). Rare endocrine and metabolic
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Figure 2. Proportion of resources by therapeutic area.
conditions are, for example, homocystinuria (betaine) and Wilson’s disease (zinc acetate dihydrate).
One of the musculoskeletal indications is juvenile idiopathic arthritis (adalimumab and tocilizumab).
However this study covers only therapeutic areas (e.g. oncology, cardiopulmonary, endocrine and
metabolic diseases) of ODs included in the analysis. Each particular indication within the therapeutic
area has not been assessed and is therefore out of scope of the study.
The following ODs were reimbursed most frequently: sildenaﬁl (mean 17 patients per year in the
amount of C114 446), sunitinib (mean 8 patients in the amount of C60 473), levetiracetam (mean
7 patients in the amount of C5 874) and trastuzumab (mean 6 patients in the amount of C48 951)
(Figure 3).
The most expensive medicines were imiglucerase (reimbursed for 1 patient with Gaucher’s disease
in the amount of C60 205) and dasatinib (an average of C32 047 per patient per year). Drugs with the
lowest annual costs per patient were levetiracetam (mean C935) and riluzole (mean C971).
Discussion
Our study indicates that OD reimbursement constitutes the biggest part of drug reimbursement
for individual patients in Latvia. Reimbursement covers drugs which are included in the national
reimbursement list, or drugs can also be reimbursed within the framework of individual reimbursement
system. The absolute majority of ODs are not included in Latvian reimbursement list, since the main
principle of drug inclusion in the list is that drug should be therapeutically and cost effective, i.e.
decision is value based and is not speciﬁc to ODs. The National Health Service evaluates therapeutic
value, price, expected budget impact and cost-effectiveness for each drug before it is included in the
reimbursement list. However, as stated by Drummond et al., because of the small market, ODs are often
very expensive. With standard economic evaluation, these drugs usually do not prove to be cost-effective
and it, taking into account their high price, means that patient access may be limited (Drummond et al.,
2007). According to Picavet et al. orphan designated drugs have higher median price (C138.56) than
non-designated drugs (C16.55) for rare disease indications (Picavet et al., 2011). Moreover, price of an
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Figure 3. OD reimbursement for individual patients.
OD is higher for a disease with a lower prevalence (de Varax et al., 2004). Also, ODs with an alternative
have lower annual cost per patient than those without an alternative (Simoens, 2011).
Number of patients receiving ODs increased much faster (by 180.4%) than resources spent on
reimbursement of these drugs (by 32.3%), resulting in a fact that the average annual costs per patient
decreased by more than a half (52.8%). Besides, it doesn’t necessarily mean that the prices of medicines
reduced signiﬁcantly (since ODs often don’t have analogues or/and are the only treatment option within
the indication), but it’s mainly related to lack of resources in current economic situation in country.
The majority of ODs assessed are used in oncology ﬁeld. This is also supported by the fact that all
ODs included in the national reimbursement list are anticancer medicines. However this ﬁnding is not
speciﬁc for Latvian pharmaceutical market, since survey conducted by the European Organization for
Rare Diseases (Eurordis) in 2010 found that rare oncologic conditions represented 38% of authorized
ODs and 56% of patients potentially treated with these medicines (Le Cam, 2010). Similar results were
reported by Schey et al. stating that within the total budget impact 40% of the conditions, for which
ODs were marketed, were oncologic and hematological diseases, accounted for 57% of the total costs
in 2010 (Schey et al., 2011). Thus oncology is the biggest therapeutic area for ODs as entire group.
Antineoplastic drugs had the highest annual costs per patient, though they decreased most notably. One
of the most expensive drugs included in the analysis was dasatinib, which is anticancer drug as well. It
was reimbursed individually in 2008–2010, but starting from 2011 it was included in the reimbursement
list C. Thus all 3 ODs included in the reimbursement list C (imatinib, dasatinib, and nilotinib) are
indicated for Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). Another
therapeutic area for ODs is cardiopulmonary diseases which are mainly represented by pulmonary
arterial hypertension (PAH). The most frequently individually reimbursed OD was sildenaﬁl (Revatio)
in both terms: number of patients and resources spent. Sildenaﬁl is indicated for PAH treatment and it
is the same active substance produced by the same manufacturer as a blockbuster drug for treatment of
erectile dysfunction – Viagra. Ambrisentan is another drug used for PAH treatment, which had higher
annual cost per patient and was reimbursed less frequently.
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Surveys on OD availability in Europe had pointed out unacceptable delays and inequalities in rare
disease patients’ access to their medicines. Especially countries with a small population suffer from a
longerdelayinavailabilityofdrugs(Bignami,2007).Thusin2010,thenumberofpatientswithpotential
access to ODs ranged from 34% in Greece up to 98% in France. The price also varied between countries,
and in some countries it was up to 160% higher than the lowest European price (Le Cam, 2010). Another
European study found that differences in annual costs per patient between EU countries for a given OD
may reach 70% (de Varax et al., 2004). Denis et al. compared rare disease and OD markets in six
European countries. The situation on OD reimbursement in studied countries was as follows: 32 ODs
were reimbursed in Belgium (2009); 35 in France (2007); 21 in Italy (2007); 32 in The Netherlands
(2009); 28 in Sweden (2008); and 12 in Scotland (2008) (Denis et al., 2010). Newer EU Member States
are often facing budget restrictions with healthcare budgets much lower than compared to older Member
States, thereby reimbursement levels can differ (Michel and Toumi, 2012). Thus number of available
(marketed) ODs in Bulgaria was 22 and 16 of them were accessible (reimbursed) for patients in 2011.
Iskrov et al. point out that this is an important issue especially for Eastern European countries, as a
big part of ODs are not priced and reimbursed in many countries. In this geographical and economical
region the price level of ODs is not among the lowest in the EU, and that could be explained by the
small market size represented by these countries (Iskrov et al., 2012). Serbia might be mentioned as
another example, where only four ODs were reimbursed. Authors also suggest that gross domestic
product (GDP) value may partly explain differences in the level of OD reimbursement among European
countries, since Serbia is a country with a low GDP (Pavlovi´ c et al., 2012). In Lithuania budget assigned
for reimbursement of ODs is limited and insufﬁcient (6.5 million LTL, i.e. C1.89 million, in 2006),
therefore access to health care services and ODs in some cases is restricted (Spokiene, 2008).
All of the above mentioned may be related to Latvia as one of the newer EU Member States
with relatively low GDP, budgetary restrictions and a small population representing small market size.
Currently 29 ODs are available in Latvia, and only three of them are included in the reimbursement
list. Thus number of reimbursed ODs is the smallest among the all European countries included in
the analysis. Whereas ODs can also be reimbursed individually with limit of 10 000 LVL (C14 229)
per patient per year, this limit is certainly not sufﬁcient. All the other ODs, that are not reimbursed,
are practically inaccessible for Latvian patients because of their high costs. Pharmaceutical companies
have to comply with different pricing and reimbursement approaches in each EU country, thereby
raising the price of ODs (Boon and Moors, 2008). Moreover prices of drugs distributed through the
hospital pharmacies are not regulated in most European countries, but are negotiated directly between
the manufacturer and the hospital. According to Simoens, there is a need for a transparent and evidence
based approach towards pricing and reimbursement of ODs (Simoens, 2011). The economic impact of
ODs on national budget is growing, for example, in France representing a total budget of C1 billion
in 2009 (Michel and Toumi, 2012). The annual per patient cost of ODs varied between C1 251 and
C407 631, with the median cost being C32 242. The share of the total European pharmaceutical market
represented by ODs was 3.3% in 2010, and it was predicted by Schey et al. to increase to a peak of
4.6% in 2016 (Schey et al., 2011). Another analysis estimated that ODs constituted 1.9% of total drugs
expenditure in Belgium in 2008, and predicted it to increase to about 4% in 2013 (Denis et al., 2010),
while the average budget impact of ODs accounted for 1.7% of the total pharmaceutical expenditure
across France, Germany, Italy, Spain and the UK in 2007 (Oroﬁno et al., 2010).
Conclusions
OD reimbursement constitutes the biggest part of drug reimbursement for individual patients in
Latvia. Number of patients receiving these drugs increased, while the average annual costs per patient
decreased. The majority of patients received antineoplastic ODs followed by the drugs for treatment
of cardiopulmonary diseases. Therefore, most costs were spent to cover reimbursement of these drugs.
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Furthermore there was a tendency observed that share of antineoplastic drugs was decreasing, while
share of drugs for cardiopulmonary diseases was increasing in both terms (number of patients, and
resources spent). Antineoplastic drugs had the highest annual costs per patient, though they decreased
most notably, while drugs for diseases of the nervous system and endocrine and metabolic diseases had
the lowest costs per patient.
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